Major contribution of Innova to the Sino-Innovax J
Post# of 22456
Because Sinopharm has the 2021 goal of ramping to 7 billion dose production, a tight supply chain and anticounterfeiting are a necessity to ensure quality and security control of the product. Anticounterfeiting is needed on both vaccine dose and packaging and tests individually and packaging.
Part of the Pasaca agreement is/was that Pasaca would introduce QMC to potential clients and be compensated for that service. Sinopharm is the world's sixth largest vaccine manufacturer. That would be a great place to start.